E A Klein

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Chemoprevention of prostate cancer: an updated view
    Eric A Klein
    Glickman Urological and Kidney Institute, Desk Q10 1, 9500 Euclid Ave, Cleveland, OH 44122, USA
    World J Urol 30:189-94. 2012
  2. ncbi Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies
    Xiaoxing Qiu
    Infectious Diseases R and D, Abbott Diagnostics, 100 Abbott Park Rd, Abbott Park, IL 60064, USA
    Retrovirology 7:68. 2010
  3. ncbi Locally advanced prostate cancer
    E A Klein
    Urological Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Treat Options Oncol 2:403-11. 2001
  4. ncbi Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?
    Eric A Klein
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Urol Oncol 27:67-71. 2009
  5. ncbi What's new in prostate cancer screening and prevention?
    Eric A Klein
    Glickman Urological and Kidney Institute, Q10 1, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 76:439-45. 2009
  6. ncbi Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44122, USA
    Urology 68:1145-51. 2006
  7. ncbi The selenium and vitamin E cancer prevention trial
    Eric A Klein
    Section of Urologic Oncology, Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, OH 44195, Cleveland, USA
    World J Urol 21:21-7. 2003
  8. ncbi Inflammation, infection, and prostate cancer
    Eric A Klein
    Glickman Urologic and Kidney Institute, Cleveland, Ohio, USA
    Curr Opin Urol 18:315-9. 2008
  9. ncbi SELECT: the selenium and vitamin E cancer prevention trial
    Eric A Klein
    Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Urol Oncol 21:59-65. 2003
  10. ncbi Localized prostate cancer: radiation or surgery?
    Eric A Klein
    Section of Urology Oncology, Urological Institute, Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Urol Clin North Am 30:315-30, ix. 2003

Detail Information

Publications114 found, 100 shown here

  1. ncbi Chemoprevention of prostate cancer: an updated view
    Eric A Klein
    Glickman Urological and Kidney Institute, Desk Q10 1, 9500 Euclid Ave, Cleveland, OH 44122, USA
    World J Urol 30:189-94. 2012
    ..To place chemoprevention of prostate cancer in current clinical context...
  2. ncbi Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies
    Xiaoxing Qiu
    Infectious Diseases R and D, Abbott Diagnostics, 100 Abbott Park Rd, Abbott Park, IL 60064, USA
    Retrovirology 7:68. 2010
    ..Development of assays to detect XMRV-specific antibodies would greatly facilitate such studies. However, the nature and kinetics of the antibody response to XMRV infection have yet to be determined...
  3. ncbi Locally advanced prostate cancer
    E A Klein
    Urological Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Treat Options Oncol 2:403-11. 2001
    ..However, the optimal form of aggressive therapy for these patients is unknown...
  4. ncbi Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?
    Eric A Klein
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Urol Oncol 27:67-71. 2009
    ..The results suggest similar short-term survival but domain-specific effects on QOL after treatment with radical prostatectomy, brachytherapy, or external beam radiotherapy...
  5. ncbi What's new in prostate cancer screening and prevention?
    Eric A Klein
    Glickman Urological and Kidney Institute, Q10 1, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 76:439-45. 2009
    ..Two large trials of screening with prostate-specific antigen (PSA) measurements came to seemingly opposite conclusions. Furthermore, a large trial of selenium and vitamin E found that these agents have no value as preventive agents...
  6. ncbi Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44122, USA
    Urology 68:1145-51. 2006
  7. ncbi The selenium and vitamin E cancer prevention trial
    Eric A Klein
    Section of Urologic Oncology, Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, OH 44195, Cleveland, USA
    World J Urol 21:21-7. 2003
    ....
  8. ncbi Inflammation, infection, and prostate cancer
    Eric A Klein
    Glickman Urologic and Kidney Institute, Cleveland, Ohio, USA
    Curr Opin Urol 18:315-9. 2008
    ..Recent evidence suggesting that inflammation and infection play a role in the etiology of prostate cancer, and the discovery of a novel virus in men with a genetic susceptibility to prostate cancer is reviewed...
  9. ncbi SELECT: the selenium and vitamin E cancer prevention trial
    Eric A Klein
    Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Urol Oncol 21:59-65. 2003
    ..SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men...
  10. ncbi Localized prostate cancer: radiation or surgery?
    Eric A Klein
    Section of Urology Oncology, Urological Institute, Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Urol Clin North Am 30:315-30, ix. 2003
    ..The available data suggest that these two modalities provide similar rates of cancer control at 10 years, and that except for the youngest patients, choice of therapy should be based on toxicity and QOL issues...
  11. ncbi Chemoprevention of prostate cancer
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute and Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Annu Rev Med 57:49-63. 2006
    ..The current body of evidence is insufficient to make a routine recommendation of any dietary or nutritional supplement for the prevention of prostate cancer...
  12. ncbi Update on chemoprevention of prostate cancer
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Curr Opin Urol 14:143-9. 2004
    ..This overview summarizes the results of that trial, the design of other large-scale trials, and advances in understanding of the molecular mechanisms underlying the effect of other promising agents...
  13. ncbi Can prostate cancer be prevented?
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute
    Nat Clin Pract Urol 2:24-31. 2005
    ..Ultimately, the adoption of a preventive strategy hinges on its potential benefits weighed against the potential risks of the specific agents used...
  14. ncbi Chemoprevention of prostate cancer
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland, OH 44195, USA
    Crit Rev Oncol Hematol 54:1-10. 2005
    ....
  15. ncbi Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Eric A Klein
    Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    JAMA 306:1549-56. 2011
    ..Longer follow-up and more prostate cancer events provide further insight into the relationship of vitamin E and prostate cancer...
  16. ncbi Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland, OH 44195, USA
    J Clin Oncol 23:7460-6. 2005
    ....
  17. ncbi Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories
    Eric A Klein
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
    J Urol 179:2212-6; discussion 2216-7. 2008
    ..In the current study we determined whether the effects of the learning curve are modified by patient risk, as defined by preoperative tumor characteristics...
  18. ncbi Selenium and vitamin E cancer prevention trial
    Eric A Klein
    Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Ann N Y Acad Sci 1031:234-41. 2004
    ..SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001, with final results anticipated in 2013...
  19. ncbi Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening
    Michael Aleman
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 62:70-4. 2003
    ..These observations suggest that younger men with a lower PSA are more likely to have organ-confined and curable disease at diagnosis. This information has important implications for counseling and screening...
  20. ncbi PSA bounce predicts early success in patients with permanent iodine-125 prostate implant
    Chandrika Patel
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 63:110-3. 2004
    ..A PSA bounce may be associated with improved bRFS but was not associated with any of the pretreatment clinical and dosimetric factors examined...
  21. ncbi Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer
    Christopher J Weight
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 65:347-50. 2006
    ..45). PNI did not correlate with biochemical relapse free survival (p = 0.40). CONCLUSION: Perineural invasion is not a significant predictor of biochemical recurrence in patients undergoing brachytherapy for prostate cancer...
  22. ncbi No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer
    Nivedita Bhatta-Dhar
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 63:528-31. 2004
    ..Such patients can be spared the morbidity and cost of PLND without affecting the chance for cure...
  23. ncbi Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer
    P A Kupelian
    Department of Radiation Oncology, Cleveland Clinic Foundation, OH 44195, USA
    Int J Radiat Oncol Biol Phys 46:567-74. 2000
    ..To study the effect on biochemical relapse-free survival (bRFS) and clinical disease-free survival of radiation doses delivered to the prostate and periprostatic tissues for localized prostate cancer...
  24. ncbi Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer un
    John Thomas
    Urological Institute, Taussig Cancer Center, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Clin Oncol 20:3213-8. 2002
    ..This assay has no clinical utility in this patient population...
  25. ncbi Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration
    Hadley M Wood
    Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 178:1271-6. 2007
    ..Our hypothesis was that the gap in biochemical relapse-free survival between these groups would lessen in the later prostate specific antigen era due to catch-up awareness/availability of screening and treatment in the black population...
  26. ncbi Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer
    Ayman S Moussa
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    BJU Int 103:43-8. 2009
    ....
  27. ncbi Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10)
    P A Kupelian
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 50:621-5. 2001
    ..e., Stage T1-T2, biopsy Gleason score (bGS) < or = 6, and pretreatment prostate-specific antigen (iPSA) < or = 10 ng/mL...
  28. ncbi Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer
    P E Clark
    Urology Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Urology 57:281-5. 2001
    ..Additional study of this paradigm with other drug regimens is warranted...
  29. ncbi Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer
    Michael W Kattan
    Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer 115:1005-10. 2009
    ..The purpose of this study was to develop and internally validate nomograms to predict the probability of recurrence, both preoperatively and postoperatively, with adjustment for standard parameters plus surgeon experience...
  30. ncbi Surgical management of prostate cancer: advances based on a rational approach to the data
    Anoop M Meraney
    Glickman Urological Institute A-100, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Eur J Cancer 41:888-907. 2005
    ..Radical prostatectomy is also appropriate in selected patients with locally advanced disease and after failed radiation therapy...
  31. ncbi Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate
    Aimee L Quan
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 68:1237-41. 2006
    ..0069 and P = 0.0255, respectively). No association was found between gland size/width and postimplant dosimetry. CONCLUSIONS: The results of our study have shown that implantation of large/wide prostates independently confers better bRFS...
  32. ncbi Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer
    Robert Dreicer
    Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 63:1138-42. 2004
    ..Additional study of this paradigm with other agents alone and in combination with docetaxel seems warranted...
  33. ncbi Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy
    D R Shepard
    Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
    J Urol 181:1672-7; discussion 1677. 2009
    ..The efficacy and safety of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel, Abraxane), a novel nanoparticle based formulation, were assessed in patients with high risk, locally advanced prostate cancer...
  34. ncbi Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series
    Christopher J Weight
    Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195 0001, USA
    Cancer 115:792-9. 2009
    ..The outcome of NC and open radical cystectomy (RC) was evaluated in a contemporary cohort of patients in a tertiary referral setting...
  35. ncbi Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    JAMA 291:1325-32. 2004
    ..Selected patients with high-grade disease and/or a rapid PSADT who were previously thought to be destined to develop progressive metastatic disease may achieve a durable response to salvage radiotherapy...
  36. ncbi Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
    Deepak Khuntia
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Cancer 100:1283-92. 2004
    ..001). CONCLUSIONS: The most significant therapeutic factor affecting bRFS rates after RT was radiation dose, rather than AD therapy use or radiation technique...
  37. ncbi Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma
    Anil A Thomas
    Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Urol 181:518-23; discussion 523. 2009
    ..We assessed the activity of neoadjuvant sunitinib on primary renal tumors in patients with advanced renal cell carcinoma as well as the feasibility and safety of subsequent surgical resection...
  38. ncbi Management of clinical stage I nonseminomatous germ cell testicular cancer
    Toni K Choueiri
    Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    Urol Clin North Am 34:137-48; abstract viii. 2007
    ..For patients at high risk for relapse and who are not candidates for surveillance, we believe the evidence supports RPLND over primary chemotherapy...
  39. ncbi Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy
    Matthew N Simmons
    Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue A100, Cleveland, OH 44195, USA
    Eur Urol 51:1175-84. 2007
    ..While a rising PSA level universally antedates metastatic progression and prostate cancer-specific mortality (PCSM), it is not a surrogate for these endpoints. Thus, the management of patients with BCR is controversial...
  40. ncbi Dosimetric comparison of pre-planned and or-planned prostate seed brachytherapy
    D A Wilkinson
    Department of Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 48:1241-4. 2000
    ..Computer generated treatment plans were used in both procedures...
  41. ncbi Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients
    P L Paris
    Department of Cancer Biology, Cleveland Clinic Foundation, Ohio 44195, USA
    Cancer Epidemiol Biomarkers Prev 8:901-5. 1999
    ..Among the patients, those who were homozygous for the CYP3A4 variant were more likely to present with clinically more advanced prostate cancer...
  42. ncbi Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray
    M Skacel
    Department of Anatomic, The Urology Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hum Pathol 32:1392-7. 2001
    ..Chromosome 7 abnormalities may play an important role in cancer progression in margin-negative patients. EGFR amplification was rare, suggesting that this oncogene is not altered at the gene copy number level...
  43. ncbi Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection
    Nivedita Bhatta Dhar
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    BJU Int 98:1172-5. 2006
    ....
  44. ncbi Prostate cancer volume at biopsy predicts clinically significant upgrading
    Fei Dong
    Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    J Urol 179:896-900; discussion 900. 2008
    ..We identified clinical and pathological parameters that predict pathological upgrading in this population...
  45. ncbi A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance
    Vairavan S Subramanian
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Nat Clin Pract Urol 5:220-3. 2008
    ..Serologic relapse at 4 months after orchiectomy was successfully treated with bleomycin, etoposide and cisplatin (BEP) chemotherapy...
  46. ncbi Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE
    Ryan K Berglund
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Urol 177:526-29; discussion 529-30. 2007
    ..We compared 5-year treatment failure rates in patients with low, intermediate and high risk disease who underwent radical prostatectomy with or without pelvic lymph node dissection...
  47. ncbi The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival
    Carvell T Nguyen
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
    J Urol 181:75-80. 2009
    ..Various schemes based on clincopathological criteria have been proposed to stratify cases by presumed recurrence risk. We determined whether survival outcomes are dependent on the specific definition...
  48. ncbi Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy
    Brian R Lane
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 72:1240-5. 2008
    ..The results from 3 retrospective studies have suggested that low pretreatment testosterone is an independent predictor of adverse pathologic features in patients with localized prostate cancer...
  49. ncbi Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E Cancer Prevention Trial
    Eric A Klein
    Section of Urologic Oncology, Urologic Institute, Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Recent Results Cancer Res 163:212-25; discussion 264-6. 2003
    ....
  50. ncbi Aggressiveness of familial prostate cancer
    Patrick A Kupelian
    Glickman Urological Institute and Radiation Oncology Department, Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 24:3445-50. 2006
    ..To report on the aggressiveness of sporadic versus familial prostate cancer...
  51. ncbi Nonseminomatous germ cell tumor after chemotherapy with residual mass invading the spine: part 2
    Ryan K Berglund
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland, OH 44195, USA
    Eur Urol 50:607-8. 2006
  52. ncbi Peritumoral lymphatic invasion is associated with regional lymph node metastases in prostate adenocarcinoma
    Andres A Roma
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mod Pathol 19:392-8. 2006
    ....
  53. ncbi Continuing trends in pathological stage migration in radical prostatectomy specimens
    Ithaar H Derweesh
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Urol Oncol 22:300-6. 2004
    ..1% for 1987 to 1994 and 82.6% for 1995 to 2001 (P-value = 0.0022). PSA screening has resulted in a downward pathological stage migration. These observations demonstrate improved biochemical failure rates in more recently treated patients...
  54. ncbi Laparoscopic radical cystectomy and continent orthotopic ileal neobladder performed completely intracorporeally: the initial experience
    Inderbir S Gill
    Section of Laparoscopic and Minimally Invasive Surgery, Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Urol 168:13-8. 2002
    ..CONCLUSIONS: Laproscopic radical cystectomy and orthotopic ileal neobladder performed completely intracorporeally are feasible...
  55. ncbi Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above
    Patrick A Kupelian
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Cancer 95:2302-7. 2002
    ..To review the biochemical recurrence-free survival (bRFS) rates of treatment with either external beam radiotherapy or radical prostatectomy in patients with biopsy Gleason score 8 or above in the prostate specific antigen (PSA) era...
  56. ncbi Phase II trial of GM-CSF in advanced prostate cancer
    R Dreicer
    Department of Hematology Oncology, Cleveland Clinic Foundation, OH 44195, USA
    Invest New Drugs 19:261-5. 2001
    ..The purpose of this study was to evaluate the activity of granulocyte macrophage-colony stimulating factor in a less heavily pretreated population...
  57. ncbi Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer
    R Dreicer
    Department of Hematology/Oncology, Taussig Cancer Center and the Urologic Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Semin Oncol 28:45-8. 2001
    ..The neoadjuvant use of investigational cancer therapies may allow for relatively rapid assessment of their antitumor activity...
  58. ncbi SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial
    E A Klein
    Section of Urologic Oncology, Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Urol 166:1311-5. 2001
    ..CONCLUSIONS: SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment in the study is planned to begin in 2001 with final results anticipated in 2013...
  59. ncbi Use of nomograms for early detection in prostate cancer
    Devon C Snow
    Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195, USA
    J Natl Compr Canc Netw 8:271-6. 2010
    ..This article discusses the rational for the use of nomograms and the advantages and limitations for the most commonly used nomograms...
  60. ncbi Paracolic recurrence of stage I seminoma
    Louis Kantzavelos
    Section of Urologic Oncology, Glickman Urologic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Urology 62:145. 2003
    ..We describe a paracolic recurrence outside of the standard radiation field of a low-stage pure seminoma that was managed by chemotherapy and surgical excision, rendering the patient disease free with short-term follow-up...
  61. ncbi The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy
    Michael C Lee
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
    Eur Urol 58:90-5. 2010
    ..Few reports attempt to validate the role of Epstein criteria in selecting patients for an active surveillance protocol...
  62. ncbi Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
    Andrew J Stephenson
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    J Clin Oncol 25:2035-41. 2007
    ..We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence...
  63. ncbi The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Urology 75:467-71. 2010
    ..To assess the relationship between prostate-specific antigen (PSA) testing frequency and biochemical failure (bF) and clinical failure (cF)...
  64. ncbi Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era
    Patrick A Kupelian
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 52:704-11. 2002
    ..To study the impact of biochemical failure on overall survival rates during the first 10 years after definitive radiotherapy for localized prostate cancer...
  65. ncbi Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer
    Christopher J Weight
    Section of Urologic Oncology, Glickman Urologic Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Urology 71:141-5. 2008
    ..To compare the long-term differences in actuarial biochemical relapse-free survival rates from a contemporary series of patients who underwent radical prostatectomy with and without pelvic lymph node dissection (PLND)...
  66. ncbi Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants
    Benjamin T Larson
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, Ohio, USA
    J Urol 179:1344-8. 2008
    ..We assessed a series of men undergoing radical prostatectomy for clinical and pathological measures of tumor aggressiveness according to the RNASEL R462Q genotype...
  67. ncbi Brachytherapy or surgery? A composite view
    Jay P Ciezki
    Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Oncology (Williston Park) 23:960-4. 2009
    ..This review will focus the comparison on toxicity, the "soft" endpoints of biochemical relapse-free survival and clinical relapse-free survival, and the "hard" endpoint of prostate cancer-specific mortality...
  68. ncbi Epidermoid cyst of the testicle
    Armine Karapetian Smith
    Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH 44195, USA
    Urology 74:544. 2009
    ..We report on a case of testicular mass with classic radiographic appearance for epidermoid cyst...
  69. ncbi Podocalyxin variants and risk of prostate cancer and tumor aggressiveness
    Graham Casey
    Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Hum Mol Genet 15:735-41. 2006
    ..48, 95%CI=1.02-2.14, P=0.04). These results implicate PODXL as a candidate prostate cancer tumor aggressiveness gene mapping to chromosome 7q32-q33...
  70. ncbi Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer
    Robert Dreicer
    Department of Hematology Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Urol Oncol 23:82-6. 2005
    ..We performed a Phase II trial of this combination to assess its toxicity and potential utility as an immunomodulatory approach to management of advanced prostate cancer...
  71. ncbi Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis
    Ryan K Berglund
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 67:1253-6. 2006
    ..Furthermore, RP results in short-term biochemical recurrence-free survival similar to that of combined radiotherapy and androgen ablation...
  72. ncbi PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time
    Jay P Ciezki
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 64:512-7. 2006
    ..To analyze prostate-specific antigen (PSA) kinetics in patients treated with prostate brachytherapy (PI) with a minimum of 5 years of PSA follow-up...
  73. ncbi The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome
    Robert H Silverman
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Nat Rev Urol 7:392-402. 2010
    ..Emerging science surrounding XMRV is contributing to our knowledge of retroviral infections while focusing intense interest on two major human diseases...
  74. ncbi Association of body mass index with prostate cancer biochemical failure
    David Ly
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
    J Urol 183:2193-9. 2010
    ..We determined whether there is an association between body mass index and biochemical failure in men treated for low and intermediate risk prostate cancer with various treatment modalities...
  75. ncbi RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases
    Graham Casey
    Department of Cancer Biology, ND50, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Nat Genet 32:581-3. 2002
    ..Men that are heterozygous with respect to the mutated allele have 50% greater risk of prostate cancer than non-carriers, and homozygotes have more than double the risk...
  76. ncbi Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation
    Andrew D Vassil
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
    Urology 76:1251-7. 2010
    ....
  77. ncbi Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy
    Patrick A Kupelian
    Department of Radiation Oncology, Desk 728, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Clin Oncol 20:3376-85. 2002
    ..To review biochemical relapse-free survival (bRFS) rates after either external-beam radiotherapy (RT) or radical prostatectomy (RP) for localized prostate cancer...
  78. ncbi Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels
    Andrew J Stephenson
    Section of Urologic Oncology, Glickman Urological and Kidney Institute, Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio 44195 0001, USA corrected
    Eur Urol 55:610-6. 2009
    ..5 ng/ml) given the 17% prostate cancer (pCA) detection rate at PSA of 1.1-2.0. The outcome of patients treated at PSA < or = 2.5 is poorly defined, and advantages associated with such an early diagnosis are uncertain...
  79. ncbi Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma
    Jorge A Garcia
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Clin Cancer Res 14:3052-9. 2008
    ..This study assessed the biological effects and safety of GM-CSF and thalidomide in patients with localized prostate cancer before radical prostatectomy...
  80. ncbi Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy
    Andrew J Stephenson
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
    J Urol 182:1357-63. 2009
    ..In a multicenter study we analyzed the predictive usefulness of several subclassifications of positive surgical margins...
  81. ncbi A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy
    Jay P Ciezki
    Department of Radiation Oncology, The Glickman Urological Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 60:1347-50. 2004
    ....
  82. ncbi Ejaculatory urine incontinence after radical prostatectomy
    Robert Abouassaly
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 68:1248-52. 2006
    ..We attempt to further describe and assess the phenomenon of urinary incontinence with ejaculation in a series of patients...
  83. ncbi Chemoprevention of prostate cancer
    Andrew J Stephenson
    Glickman Urological and Kidney Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk Q10 1, Cleveland, OH 44195 0001, USA
    Urol Clin North Am 37:11-21, Table of Contents. 2010
    ..5alpha-reductase inhibitors represent an effective primary prevention strategy, and these agents should be used more liberally for the prevention of prostate cancer, particularly in high-risk patients...
  84. ncbi Alterations of transforming growth factor beta receptor II, insulin growth factor receptor II genes in microsatellite unstable prostate carcinomas
    Nandan Bhattacharyya
    Department of Cancer Biology, NB40, Lerner Research Institute, Department of Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Oncol Rep 11:231-6. 2004
    ..On the other hand, 4 tumors showed changes within the 5CT repeats. In addition, 3 tumors showed another novel insertion of C within the CT repeats...
  85. ncbi Complete resection of seminal vesicles at radical prostatectomy results in substantial long-term disease-free survival: multi-institutional study of 6740 patients
    Angelo Baccala
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44122, USA
    Urology 69:536-40. 2007
    ..To estimate the disease-specific survival of patients with complete removal of the seminal vesicles (SVs) at radical prostatectomy and to develop a nomogram for the prediction of SV invasion (SVI)...
  86. ncbi Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis
    Carvell T Nguyen
    Glickman Urological and Kidney Institute, Cleveland Clinic, 9500 Euclid Ave, Desk Q10, Cleveland OH, 44195 0001, USA
    J Clin Oncol 28:119-25. 2010
    ..Surveillance was the preferred intervention for all except those patients at high risk for relapse...
  87. ncbi Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study
    Cristina Magi-Galluzzi
    Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer 110:1248-54. 2007
    ..The objective of the current study was to determine the histologic and molecular changes that occurred in patients with high-risk, localized prostate cancer (PCa) after neoadjuvant docetaxel chemotherapy...
  88. ncbi Surgical management of low-stage nonseminomatous germ cell testicular cancer
    Andrew J Stephenson
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195 0001, USA
    BJU Int 104:1362-8. 2009
    ..The therapeutic efficacy of laparoscopic RPLND is not proven and currently should be considered a staging procedure only. Adjuvant chemotherapy after RPLND is typically restricted to patients with pathological stage N2-3 disease...
  89. ncbi Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer
    Michael J Burdick
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44113, USA
    Int J Radiat Oncol Biol Phys 73:1439-45. 2009
    ..Most of the present data regarding the PG of GS7 CaP refer to surgical specimens. Our goal was to determine whether the biopsy GS used at the time of medical decision making predicted for the biochemical outcome...
  90. ncbi Management of erectile dysfunction following radical prostatectomy
    C D Zippe
    Andrology Urology Research Laboratory, Urological Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, A100, Cleveland, OH 44195, USA
    Curr Urol Rep 2:495-503. 2001
    ..The potential impact of sildenafil and other new oral therapies should encourage urologists to continue to perform and perfect the nerve-sparing approach...
  91. ncbi Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome
    P A Kupelian
    Department of Radiation Oncology, Cleveland Clinic Foundation, OH 44195, USA
    J Clin Oncol 15:1478-80. 1997
    ..To determine if familial prostate cancer patients have a less favorable prognosis than patients with sporadic prostate cancer after treatment for localized disease with either radiotherapy (RT) or radical prostatectomy (RP)...
  92. ncbi Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life
    P A Kupelian
    Department of Radiation Oncology, Cleveland Clinic Foundation, OH 44195, USA
    Int J Radiat Oncol Biol Phys 51:988-93. 2001
    ..To present our preliminary observations on the late toxicity and quality of life (QOL) of patients treated with short-course intensity-modulated radiotherapy (SCIM-RT)...
  93. ncbi Potential target populations and clinical models for testing chemopreventive agents
    E A Klein
    Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 57:171-3. 2001
    ..These observations give rise to many potential clinical trials of specific agents. These trials should also include collection of data on potentially confounding influences on disease development and progression...
  94. ncbi Periprostatic local anesthesia eliminates pain of office-based transrectal prostate biopsy
    J S Jones
    Urological Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Prostate Cancer Prostatic Dis 6:53-5. 2003
    ..Periprostatic injection of local anesthetic essentially eliminates pain from prostate biopsy. Nerve-sparing radical retropubic prostatectomy is not more difficult as a result...
  95. ncbi Defining sexual outcomes after treatment for localized prostate carcinoma
    Leslie R Schover
    Department of Behavioral Science, The University of Texas M D Anderson Cancer Center, Houston, Texas77030 4009, USA
    Cancer 95:1773-85. 2002
    ..The objective of this survey was to identify factors associated with good sexual outcomes in a large group of survivors of localized prostate carcinoma...
  96. ncbi Prevention of prostate cancer with finasteride: US/European perspective
    Ian M Thompson
    University of Texas Health Science Center, Division of Urology, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Eur Urol 44:650-5. 2003
    ..We herein amplify on the results of this trial to assist patients and physicians in reaching individualized decisions...
  97. ncbi Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer
    Patrick A Kupelian
    Department of Radiation Oncology, M D Anderson Cancer Center Orlando, Orlando, FL 32806, USA
    Int J Radiat Oncol Biol Phys 71:16-22. 2008
    ..To study the effect of radiation dose on local failure (LF) and distant metastasis (DM) in prostate cancer patients treated with external beam radiotherapy...
  98. ncbi Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer
    Patrick A Kupelian
    Department of Radiation Oncology, M D Anderson Cancer Center Orlando, Orlando, FL 32806, USA
    Int J Radiat Oncol Biol Phys 58:25-33. 2004
    ....
  99. ncbi First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement
    Ian M Thompson
    University of Texas Health Science Center at San Antonio, Texas 78229, USA
    J Urol 171:S3-4. 2004
  100. ncbi Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer
    Patrick A Kupelian
    Department of Radiation Oncology, M D Anderson Cancer Center Orlando, Orlando, Florida 32806, USA
    Urology 68:593-8. 2006
    ..To report biochemical relapse-free survival (bRFS) after radiotherapy (RT) for localized prostate cancer with two separate failure definitions and compare the results with those after radical prostatectomy (RP)...
  101. ncbi Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY, USA
    Radiother Oncol 71:29-33. 2004
    ....